Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, the researchers documented two instances of melasma linked to finasteride use, highlighting the need for clinicians to review medication history when treating facial hyperpigmentation, especially in individuals with darker skin types.

This paper reports two cases of finasteride-induced melasma, expanding the limited literature on this side effect, and underscores the importance of considering 5-ARI exposure in patients with new or persistent hyperpigmentation, especially among those with darker skin.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.

In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

In this rodent study, researchers found that the drug finasteride may reduce anxiety and depression-like behaviors in a model of aging, despite inducing metabolic disturbances and depressive-like behaviors in young rats, suggesting potential considerations for its use in elderly populations.

In this study, chronic exposure to finasteride induced metabolic disturbances and depression-like behaviors in young male rats, similar to those caused by obesity, but did not worsen anxiety or depression in obese rats.

This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

This review analyzed current research on finasteride and dutasteride and found insufficient evidence to fully elucidate their role in metabolic adverse events, such as liver disease and diabetes, due to a lack of detailed pathophysiologic understanding; further studies are needed to clarify these mechanisms.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Dutasteride and finasteride don't raise erectile dysfunction risk.

This article discusses how 5-alpha-reductase inhibitors like finasteride and dutasteride are used to treat androgenetic alopecia, while highlighting the ongoing debate over their potential side effects, including sexual dysfunction and psychological issues.

This review discusses the efficacy and safety of oral finasteride for treating male pattern baldness and the potential persistent side effects, but no new results are reported.